# Consensus checked against original sources: Pasteurized Akkermansia and Metabolic Health

Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## Pilot marker benefit versus clinical glycemia
Consensus reports improved insulin/HOMA with unchanged fasting glycemia/HbA1c. Selected original Methods and Results independently confirm HOMA calculation, unchanged fasting glycemia and HbA1c, and a not-markedly-hyperglycemic baseline. These clinical nulls do not erase the genuine marker effects or demonstrate ineffectiveness in every population. [Original PMID31263284](https://pubmed.ncbi.nlm.nih.gov/31263284/). Access: full_text_partial.

## Baseline imbalance and analyzed participants
Consensus identifies 40 enrolled and 32 completers. The original body confirms 11 placebo, 12 pasteurized and nine live completers after personal, antibiotic-use and protocol exclusions, with higher insulin/lower sensitivity in the pasteurized group at baseline. This imbalance and completion analysis limit a definitive clinical interpretation; the provider summary does not replace those Methods details. [Original PMID31263284](https://pubmed.ncbi.nlm.nih.gov/31263284/). Access: full_text_partial.

## Larger trial primary null and exploratory scope
Consensus describes the 142-person trial primary Matsuda null with subsequent low-baseline marker signals. The examined original abstract confirms the intention-to-treat primary null and labels subsequent analyses exploratory, including weight P=.06 in low-baseline participants. We did not obtain its complete Methods/Results through the attempted public route, so detailed recruitment disruptions and full analysis-plan claims in the provider are not treated as independently verified body findings. [Original PMID42343233](https://pubmed.ncbi.nlm.nih.gov/42343233/). Access: abstract_metadata.

## Genuine product-specific weight-maintenance benefit
Consensus correctly preserves lower 24-week regain after an eight-week diet lead-in. The original abstract confirms 90 participants, the maintenance outcome and lower regain with MucT than placebo. This is openly scored as supplemental SC5 added after discovery; the primary glycemic/function gate remains unchanged. Pre-maintenance lead-in eligibility precedes assessed regain and does not exclude later regain failures retrospectively. [Original PMID42120725](https://pubmed.ncbi.nlm.nih.gov/42120725/). Access: abstract_metadata.

## Different-strain function and absence of measurement
The provider says direct human trials show no measurable physical-function gains while citing MucT metabolic/maintenance studies and does not use HB05 as a named supporting anchor. A missing endpoint is not a tested null. Our selected HB05 original Methods/Results show a different strain in older adults, positive left/combined extensor torque, unchanged grip and myostatin, and per-protocol analysis. Those positives remain real but cannot be extrapolated to MucT clinical metabolism. [Original PMID39683431](https://pubmed.ncbi.nlm.nih.gov/39683431/). Access: full_text_partial.

## Review-mediated mixture statement checked against its original
Consensus supports its multi-strain glucose/HbA1c statement through review/mechanism citations. Our examined WBF-011 original instead supplies the direct 76-person 12-week trial: the five-strain/inulin mixture improves postprandial glucose and reports a HbA1c signal. This specific product evidence cannot isolate Akkermansia component necessity or validate other commercial formulas. Reviews do not add primary-count credit. [Original PMID32675291](https://pubmed.ncbi.nlm.nih.gov/32675291/). Access: abstract_metadata.

## Live strain full-population null versus baseline subgroup
Consensus separates live WST01 from pasteurized MucT. The original 58-person 12-week trial abstract confirms no overall HbA1c/weight advantage and low-baseline colonization/clinical signals. Baseline abundance is measurable before outcomes, but exploratory subgroup and within-group significance cannot automatically establish a prospective replicated treatment interaction. [Original PMID39879980](https://pubmed.ncbi.nlm.nih.gov/39879980/). Access: abstract_metadata.

## Yogurt endpoints and untested physical fitness
Consensus reports selected postbiotic-yogurt anthropometric benefits and says physical fitness was not altered. The original abstract reports waist, fat, AST and appetite comparisons over eight weeks, without a documented physical-fitness contrast. We preserve its product-specific positive endpoints and treat physical function as not established from the examined record, rather than infer a measured null. [Original PMID40451504](https://pubmed.ncbi.nlm.nih.gov/40451504/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.